An Open-Label, Multicenter, Dose Escalation And Expansion Study Of SHR7280 In Subjects With Hormone Sensitive Prostate Cancer
Latest Information Update: 26 Sep 2023
At a glance
- Drugs SHR 7280 (Primary)
- Indications Adenocarcinoma; Prostate cancer
- Focus Adverse reactions
- Sponsors Jiangsu Hengrui Medicine Co.
Most Recent Events
- 17 Sep 2023 Status changed from recruiting to completed.
- 13 Jan 2022 Status changed from not yet recruiting to recruiting.
- 13 Aug 2021 New trial record